Royalty Pharma (RPRX) Q2 2026 earnings review
Core Royalties Accelerate Despite Headline Milestone Drag
Royalty Pharma delivered a fundamentally robust Q2, though headline numbers mask the underlying strength. While total Portfolio Receipts grew just 6% YoY to $773M, core Royalty Receipts accelerated to 14% growth ($768M). This divergence was driven by a 91% collapse in volatile milestone payments. The core portfolio easily absorbed the expected generic hit to Promacta (down 75%), powered by massive gains in Tremfya (+53%) and Voranigo (+72%). Furthermore, the manager internalization is paying off immediately, crushing operating costs to just 4.8% of receipts. Management raised FY26 guidance, confirming confidence in the underlying compounding engine.
🐂 Bull Case
Royalty Receipts grew 14% YoY, an acceleration from 13% in Q1 and 11% in FY25, proving the portfolio's capacity to absorb major generic LOEs (like Promacta) and still compound at double digits.
Payments for operating and professional costs dropped to 4.8% of Portfolio Receipts, a massive improvement from the 8.9% rate in FY25 prior to the manager internalization. This drops directly to the bottom line.
🐻 Bear Case
Total Portfolio Receipts grew only 6%, dragged down by a 91% collapse in milestone payments. This lumpiness complicates forecasting and dilutes headline growth.
Generic competition for Promacta crushed segment receipts by 75% YoY. While expected, it removes a historically stable $130M+ annual revenue stream.
⚖️ Verdict: 🟢
Bullish. The 6% top-line growth is a mirage caused by milestone timing. The actual business—collecting recurring royalties—accelerated to 14% growth, margins expanded significantly, and guidance was raised. The compounding model is working as designed.
Key Themes
Tremfya and Voranigo Power the Core Portfolio
Growth is being driven by high-momentum clinical assets. Tremfya royalties surged 53% YoY to $57M, benefiting from strong immunology demand and new approvals. Voranigo royalties accelerated 72% YoY to $46M, establishing it as a new core pillar just a year into its launch trajectory.
Aggressive Capital Deployment Continues
Management executed $1.1B in capital deployment by August 2026, including the $425M acquisition of a royalty on AstraZeneca’s cliramitug. The development-stage pipeline now holds 19 therapies, securing future growth cohorts as older assets (like Promacta and Tysabri) face generic or biosimilar headwinds.
Cost Structure Transformation Complete
The May 2025 internalization of the external manager has structurally shifted the company's margin profile. Operating and professional costs consumed just 4.8% of Portfolio Receipts in Q2, down from a historical average near 9%. This structural cost reduction guarantees higher free cash flow conversion going forward.
Macro Backdrop: Trillion-Dollar R&D Spend Unlocks Deals
The macro environment for Biopharma funding remains a massive tailwind. With global biopharma R&D spend projected to exceed $1 trillion over the next five years, Royalty Pharma is capitalizing on the need for alternative, non-dilutive capital. This dynamic is driving the surge in synthetic royalties and R&D co-funding deals, insulating the company from broader macro interest rate volatility.
Promacta LOE Destroys Segment Revenue
The long-anticipated generic competition for Promacta is officially severely impacting results. Receipts plummeted 75% YoY in Q2 to just $8M (down from $33M a year ago, and $44M in 24Q4). While management modeled this headwind, it represents a permanent loss of high-margin cash flow that forces the rest of the portfolio to work harder.
Milestone Volatility Contradicts Top-Line Narrative
While management touts 'consistent compounding,' the total Portfolio Receipts metric tells a lumpier story. Q2 Milestones and other contractual receipts crashed 91% YoY ($5M vs $56M). This specific drop dragged the company's total Portfolio Receipts growth down to 6%, significantly lagging the 14% growth of the actual underlying royalties.
Vertex Arbitration Overhang Persists
Though not explicitly updated in the Q2 press release, the ongoing dispute with Vertex regarding the Alyftrek royalty rate (currently receiving 4% vs the claimed 8%) remains a major unresolved issue. As disclosed in Q1, arbitration is not expected to conclude until mid-2027, leaving a cloud of uncertainty over one of the company's largest franchises.
Product Innovation: Pipeline Maturation
Significant clinical de-risking continues to validate the development-stage strategy. Revolution Medicines’ daraxonrasib (pancreatic cancer) was accepted for FDA review and started EMA accelerated review, while Amgen’s Imdelltra (small cell lung cancer) secured EC approval. These targeted oncology innovations are critical to bridging the gap to the 2030 portfolio targets.
Other KPIs
Accelerating. Grew 16% YoY compared to $633 million in 25Q2. This massive margin expansion (EBITDA margin reached 95% of Portfolio Receipts) is a direct result of eliminating the legacy management fee. Operating cash flow conversion remains exceptional.
Accelerating. Grew 15% YoY. This is the primary non-GAAP liquidity measure the company uses to fund dividends, buybacks, and new acquisitions. Net interest paid was virtually zero in the quarter (due to timing and interest earned), allowing 100% of Adjusted EBITDA to drop to Portfolio Cash Flow.
Decelerating. Declined 16% YoY from $44 million. Imbruvica continues to face intense competitive pressure in the CLL market from next-generation BTK inhibitors, remaining one of the few weak spots in the active commercial portfolio.
Guidance
Accelerating. Raised from the previous range of $3,325 - $3,450 million. The midpoint ($3,450M) implies roughly 6% growth over FY25's $3,254M. More importantly, management noted this incorporates expected underlying Royalty Receipts growth of 7% to 10%, showing strong core momentum.
Stable vs prior guidance. Confirms a structural, permanent decrease from the 8.9% printed in FY25 following the internalization transaction. This implies roughly $207 million in total operating costs at the guidance midpoint.
Stable vs prior guidance. Interest payments are highly back-half weighted, with ~$175 million expected in Q3 2026. This reflects the carrying cost of the company's $9.2 billion debt load used to fund its acquisition spree.
Key Questions
China Expansion Progress
In prior quarters, you highlighted the build-out of an Asia-Pacific team (led by Ken Sun) to target out-licensing royalties from Chinese biotechs. Has this translated into actionable pipeline additions yet, and what is the competitive landscape for these specific assets?
Vertex Arbitration Confidence
With the Vertex arbitration delayed until mid-2027, how does this prolonged uncertainty impact your willingness to underwrite future synthetic deals involving complex, tiered royalty structures?
Capital Return Strategy
You repurchased $45 million in stock this quarter, a relatively modest amount compared to prior periods. With $812 million in cash and an undrawn revolver, is the near-term bias heavily skewed toward M&A deployment rather than aggressive share buybacks?